noproblemtrade

[TimAlerts] COLL - Received FDA approval for Xtampza® ER, Company’s lead opioid analgesic with abuse-deterrent properties Announced U.S. commercial launch of Xtampza ER Reported positive results from a clinical study comparing effect of physical manipulation of Xtampza ER with the abuse-deterrent version of OxyContin® Reported positive results from a clinical study evaluating Hydrocodone DETERx® as a second product candidate Licensed U.S. rights to commercialize ONSOLIS® (fentanyl buccal soluble film) fr

Page
of 7